How Does Solventum Stock Stack Up Against Its Peers?
Solventum‘s (SOLV) stock has outperformed over the past year, but how does it truly stack up against peers Omnicell (OMCL) and Veradigm (MDRX) in the evolving healthcare technology landscape as of November 21, 2025? A deeper dive reveals robust operating profitability of 8.02% and a moderate valuation with a PE ratio of 9.48. However, its modest LTM revenue growth of 2.28% and significantly lower free cash flow generation at 0.60% compared to competitors, suggest potential headwinds despite its recent 19% market strength.
- SOLV’s 8.0% operating margin, highest among peers, highlights its strategic focus on high-margin MedSurg/Health IT segments.
- SOLV’s 2.3% revenue growth, lagging OMCL but outpacing MDRX, indicates early stages of its strategic pivot from legacy businesses.
- SOLV’s 19.1% stock gain, outpacing peers, yet with a 9.5 PE, suggests tempered long-term growth expectations despite initial spin-off confidence.
Here’s how Solventum stacks up across size, valuation, and profitability versus key peers.
| SOLV | OMCL | MDRX | |
|---|---|---|---|
| Market Cap ($ Bil) | 14.4 | 1.6 | 0.5 |
| Revenue ($ Bil) | 8.4 | 1.2 | 0.6 |
| PE Ratio | 9.5 | 82.3 | -6.1 |
| LTM Revenue Growth | 2.3% | 10.7% | 1.8% |
| LTM Operating Margin | 8.0% | 1.5% | -3.3% |
| LTM FCF Margin | 0.6% | 8.0% | 14.2% |
| 12M Market Return | 19.1% | -18.4% | -55.9% |
Below we compare SOLV’s growth, margin, and valuation with peers across years
Revenue Growth Comparison
- Robinhood Stock: A Pivot The Markets Are Missing
- Triggers That Could Ignite the Next Rally In Palantir Technologies Stock
- The Hidden Dangers Facing Salesforce Stock
- Cash Rich, Low Price – Adobe Stock to Break Out?
- Does Micron Technology Stock Have More Upside?
- Has Booking Stock Quietly Become a Value Opportunity?
| LTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| SOLV | 2.3% | 0.7% | 0.8% | -0.5% | ||
| OMCL | 10.7% | -3.0% | -11.5% | 14.5% | ||
| MDRX | 1.8% | – | 1.8% | 3.8% | -65.9% |
Operating Margin Comparison
| LTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| SOLV | 8.0% | 12.6% | 20.6% | 20.8% | ||
| OMCL | 1.5% | 0.0% | -3.0% | -0.2% | ||
| MDRX | -3.3% | – | -3.3% | 13.4% | 3.3% |
PE Ratio Comparison
| LTM | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|
| SOLV | 9.5 | 23.9 | � | � | ||
| OMCL | 82.3 | 163.6 | -83.5 | 396.3 | ||
| MDRX | -6.1 | – | -12.6 | 9.8 | 4.0 |
Still not sure about SOLV stock? Consider portfolio approach.
Stock Picking Falls Short Against Multi Asset Portfolios
Markets move differently but a mix of assets smooths volatility. A multi asset portfolio keeps you invested and reduces the impact of sharp drops in any single area.
The asset allocation framework of Trefis’ Boston-based, wealth management partner yielded positive returns during the 2008-09 period when the S&P lost more than 40%. Our partner’ strategy now includes Trefis High Quality Portfolio, which has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices